Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 28, 2026
Welltower (WELL) Posts Strong Q2 Results with +25% Normalized FFO Growth and Raised 2026 Guidance

Welltower (WELL) Posts Strong Q2 Results with +25% Normalized FFO Growth and Raised 2026 Guidance

Key Takeaways

  • Normalized FFO per share of $1.60 beat the Zacks Consensus Estimate of $1.55 by 3.2%, marking a 25.0% increase year-over-year.
  • Revenue reached $3.54 billion, up 39.1% from the prior year and surpassing analyst expectations of approximately $3.36–$3.43 billion.
  • Total portfolio same-store net operating income (SSNOI) grew 15.5%, fueled by 20.5% SSNOI growth in the Seniors Housing Operating (SHO) portfolio.
  • Full-year 2026 normalized FFO guidance was raised to $6.36–$6.44 per share, up from the prior range of $6.21–$6.35.
  • The quarterly dividend was increased by 15% to $0.85 per share, reflecting confidence in sustained cash flow growth.
  • Shares jumped more than 4% in after-hours trading following the release, extending a year-to-date gain of roughly 36%.

Why This Quarter Matters for Welltower Investors

Welltower Inc. (WELL), one of the largest healthcare real estate investment trusts, reported second-quarter 2026 results on July 27, 2026, after the market close. The company owns a large portfolio of senior housing, post-acute care, and outpatient medical properties across the United States, Canada, and the United Kingdom. This release stood out because the senior housing sector continues to benefit from strong demographic trends—an aging population, higher healthcare spending among older adults, and limited new supply. Welltower’s shift toward the Seniors Housing Operating segment and its acquisition activity made the quarter a meaningful checkpoint on whether the company can maintain its growth trajectory.

The Quarter’s Reported Numbers

Welltower delivered normalized funds from operations of $1.60 per diluted share, above the Zacks Consensus Estimate of $1.55 and up 25.0% from $1.28 in the same quarter last year. This marks the fourth straight quarter of beating consensus FFO estimates. On a GAAP basis, net income attributable to common stockholders was $0.61 per diluted share, compared with $0.45 a year earlier.

Revenue totaled $3.54 billion, a 39.1% increase year-over-year that exceeded the consensus range of roughly $3.36–$3.43 billion. Growth was supported by the Amica Senior Lifestyles acquisition, which closed on April 1, 2026, and added 38 Canadian seniors housing communities for a pro rata purchase price of C$4.1 billion.

The most notable operational figure was total portfolio same-store NOI growth of 15.5%, led by 20.5% growth in the SHO portfolio. Within SHO, same-store revenue rose 9.2%, helped by a 330-basis-point occupancy gain and 5.2% RevPOR growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction to the Results

Shares of WELL closed the regular session at $248.80, down about 1.3%, as some investors waited for the print. After hours the stock rose more than 4% and traded above $258 once the FFO beat, higher guidance, and 15% dividend increase to $0.85 per share were announced. The updated full-year normalized FFO range of $6.36–$6.44 per share (from $6.21–$6.35) showed management’s confidence in the growth outlook. With the stock already up roughly 36% year-to-date and about 57% over the past twelve months, the reaction indicates investors see the results as supporting the premium valuation relative to other REITs.

Key Items to Watch Going Forward

Welltower enters the second half of 2026 with solid momentum. The raised guidance points to continued double-digit FFO growth, and the dividend increase underscores management’s outlook. Several areas will be important to monitor. Integration and performance of the Amica portfolio in Canada will be watched closely, including occupancy and RevPOR trends in those communities. The ongoing shift away from the $7.2 billion Outpatient Medical portfolio through additional dispositions will affect capital allocation and future NOI growth. The balance sheet remains supportive, with Net Debt to Adjusted EBITDA at 2.99x and roughly $9.5 billion in liquidity as of June 30, 2026. The recent issuance of C$1.15 billion in senior unsecured notes at a 3.95% weighted-average coupon provides additional flexibility. Broader industry conditions also remain favorable, with senior housing occupancy reaching about 89.9% in the second quarter and new supply staying near historic lows. Potential headwinds include higher interest costs, labor pressures, and the challenge of sustaining elevated growth rates at larger scale.

Enhancing Portfolio Analysis with AI Tools

When evaluating REITs like WELL or screening for similar healthcare real estate opportunities, I occasionally turn to Tickeron’s AI Screener. It helps filter stocks by industry, technical signals, and other criteria without manually reviewing dozens of charts. The tool has proven useful for quickly identifying names with comparable momentum characteristics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WELL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


WELL's Stochastic Oscillator sits in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

WELL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WELL as a result. In 27 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 35%.

The Moving Average Convergence Divergence Histogram (MACD) for WELL turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 16 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 39%.

WELL moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for WELL crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 29%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WELL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.

The Aroon Indicator for WELL entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. WELL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.617) is normal, around the industry mean (3.199). WELL has a moderately high P/E Ratio (104.466) as compared to the industry average of (44.369). WELL's Projected Growth (PEG Ratio) (3.660) is slightly higher than the industry average of (1.649). WELL has a moderately low Dividend Yield (0.013) as compared to the industry average of (0.053). WELL's P/S Ratio (13.316) is slightly higher than the industry average of (6.013).

Industry description

The industry includes companies that publish and market books and magazines/periodicals. John Wiley & Sons, Inc., Meredith Corporation and Scholastic Corporation are some of the biggest companies in this industry. Like many other industries, publishing companies have branched out into online/digital publications (while retaining their original print business), to capture the burgeoning market in electronic media. Business could be cyclical in certain cases, since weak consumer sentiment during an economic downturn might depress sales of some magazines and books.

Market Cap

The average market capitalization across the Publishing: Books/Magazines Industry is 16.72B. The market cap for tickers in the group ranges from 113.09K to 167.86B. WELL holds the highest valuation in this group at 167.86B. The lowest valued company is DIGI at 113.09K.

High and low price notable news

The average weekly price growth across all stocks in the Publishing: Books/Magazines Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 1%. NHPBP experienced the highest price growth at 0%, while CHCT experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Publishing: Books/Magazines Industry was 57%. For the same stocks of the Industry, the average monthly volume growth was 106% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 72
Price Growth Rating: 54
SMR Rating: 78
Profit Risk Rating: 63
Seasonality Score: 35 (-100 ... +100)
View a ticker or compare two or three
WELL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a real estate investment trust

Industry PublishingBooksMagazines

Industry
Real Estate Investment Trusts
Address
4500 Dorr Street
Phone
+1 419 247-2800
Employees
712
Web
https://www.welltower.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.